MaxVal

MaxVal
Find me on:

Recent Posts

2018 Year In Review: Patent Publication Trends

We have published the second volume of our newsletter which gives an insight into the patent publication trends of the past year. The classification has been done based on countries, companies, and more. The graphical representation of the various statistical values aim to provide an overview of how the patenting scenario has changed and the technologies which show promise for patents.

Continue reading

Three Key Areas Shaping The Landscape Of Hypertension Management Devices

Cardiovascular diseases claim 17.7 million lives annually, and account for 31% of all global deaths. Cardiovascular diseases can broadly be divided into the following types: i) hypertensive heart diseases, ii) coronary heart diseases, iii) inflammatory heart disease, iv) rheumatic heart diseases, v) stroke and vi) other cardiovascular diseases.

Continue reading

MaxVal Announces Support for USPTO’s Authentication Changes

MaxVal announces that all of our software products and services now support the USPTO’s upcoming Private PAIR changes.

Continue reading

Hot Topics in Tech | December 2018 Newsletter

In the December issue of the “Hot Topics in Tech” newsletter series, we take a glance at how mobile devices have transformed healthcare and became a crucial component in the medical field.

Continue reading

MaxVal Publishes Advanced Landscape Report on E-Cigarettes

MaxVal’s E-Cigarettes report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract actionable and predictive information. By leveraging data sciences best practices, MaxVal has constructed an interactive report that melds different yet related data sources into a comprehensive landscape, allowing the reader to dynamically explore relationships.

Continue reading

Hot Topics in Tech | November 2018 Newsletter

In this issue of the "Hot Topics in Tech" series, we provide a brief overview of the patent filing activity around implantable non-energy based devices for hypertension treatment and management. We have also presented the top technologies within this domain, leading assignees, and market information.

Continue reading

What to Know About the USPTO Access to Relevant Prior Art Initiative

The USPTO recently announced its Relevant Prior Art (RPA) Initiative, seeking to leverage electronic resources to improve an examiner’s access to relevant information from applicant’s other related applications.  These resources may include related U.S. applications, international applications under the PCT, and counterpart foreign applications by the same applicant.

Continue reading

MaxVal Publishes Advanced CRISPR-Cas9 Report

Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research.  The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research.  The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers.

Continue reading

Hot Topics in Tech | October 2018 Newsletter | Maxval

This article provides a brief overview of the role of the autonomous nervous system in managing hypertension and describes various techniques related to neurostimulation. Patents revealing various energy-based techniques for neurostimulation, and devices related thereto which are available in the market are also presented.

Continue reading

MaxVal Releases Next Generation Patent Prosecution and Business Decision Tool, symphony® AI

MaxVal announces symphony® AI, the most advanced patent prosecution tool available on the market. It leverages the Salesforce Lightning architecture to integrate public and private data into a unique solution that provides decision guidance, predictions, and unprecedented insight into clients’ portfolios.

Continue reading